Arcus Biosciences Analyst Ratings
Gilead Downgraded at Truist on Cancer Strategy
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
Arcus Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Icon (ICLR)
Barclays Sticks to Its Buy Rating for Arcus Biosciences (RCUS)
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Arcus Biosciences (RCUS) and Neurocrine (NBIX)
Arcus Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Apollo Medical Holdings (AMEH) and Arcus Biosciences (RCUS)
Buy Rating for Arcus Biosciences Amidst Strategic Shifts and Promising Clinical Trials
Maintaining Hold on Arcus Biosciences Amid Financial Stability and Clinical Uncertainty
Barclays Gives a Buy Rating to Arcus Biosciences (RCUS)
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Zai Lab (ZLAB)
Optimistic Buy Rating for Arcus Biosciences Amid Promising Clinical Data on Quemliclustat
Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR), Arcus Biosciences (RCUS) and Masimo (MASI)
Arcus Biosciences Analyst Ratings
BTIG Remains a Buy on Arcus Biosciences (RCUS)
BTIG Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Buy Rating Affirmed for Arcus Biosciences Amid Strategic Collaboration and Promising Trial Milestones
Arcus Biosciences Analyst Ratings
No Data